Mode
Text Size
Log in / Sign up

Gut-lung axis in lung cancer: soluble metabolites lead, neural pathways remain hypotheticalGut Health Links May Influence Lung Cancer Treatment Paths

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that gut-lung axis evidence in lung cancer is strongest for soluble metabolites, while neural mechanisms remain hypothetical.

This narrative review with a systematic search synthesized 168 studies on the gut-lung axis in non-small-cell and small-cell lung cancer. The authors organized evidence around three mechanistic dimensions: soluble metabolites, the metabolic-endocrine axis, and neuroimmune integration.

For soluble metabolites, including short-chain fatty acids, tryptophan metabolites, and bile acids, findings were cross-validated in clinical cohorts, animal models, and in vitro experiments. Fecal microbiota transplantation and prebiotic strategies have entered clinical trials, though effect sizes were not reported.

The metabolic-endocrine axis has a solid foundation in normal physiology, but key bridging nodes in the NSCLC disease context remain untested. For neuroimmune integration, evidence is sparse. Only support for direct transport function of the vagus nerve comes from a non-peer-reviewed preprint in a non-cancer model, and the full neuroendocrine signal transduction chain remains hypothetical.

The authors note several limitations: formal risk-of-bias assessment and GRADE evaluation were not performed, evidence for neuroimmune integration is sparse, and only one non-peer-reviewed preprint supports direct vagus nerve transport. Funding and conflicts of interest were not reported.

The review identifies mechanistic gaps in endocrine and neural dimensions as barriers to moving from correlational description to causal mechanism studies. Practice relevance is limited to highlighting these gaps rather than informing clinical decisions.

This review looked at 168 different studies to see how the gut-lung axis affects lung cancer. The gut-lung axis includes things like soluble metabolites, the metabolic-endocrine axis, and neuroimmune integration. These connections involve how the body processes nutrients and signals between different systems.

Researchers found that certain soluble metabolites, such as short-chain fatty acids and bile acids, have been tested in both animal models and human groups. Because of these findings, some treatments involving gut bacteria and prebiotics are currently in clinical trials. However, other areas are less clear. The metabolic-endocrine axis is well understood in normal health, but its specific role in non-small-cell lung cancer is not yet fully tested.

One area, known as neuroimmune integration, has very little evidence. Most of the information regarding the vagus nerve in this context comes from a single, non-peer-reviewed report. Because this is a narrative review and not a clinical trial, the findings are currently used to identify where more research is needed. These results show that while some links exist, much more study is required to understand how these systems directly affect cancer.

What this means for you:
Some gut-related metabolites show promise in lung cancer research, but many links remain unproven and hypothetical.

Common questions

What role do gut metabolites play in lung cancer?

Certain soluble metabolites, including short-chain fatty acids, tryptophan metabolites, and bile acids, have been cross-validated in clinical cohorts and animal models. Because of these findings, some strategies involving prebiotics and fecal microbiota transplantation have entered clinical trials to see if they can help.

Is the link between the gut and the nervous system proven?

Evidence for the neuroimmune integration axis is currently sparse. Most of the support for the vagus nerve's role comes from a single, non-peer-reviewed preprint in a non-cancer model. The full chain of how these signals work remains hypothetical at this time.

How much evidence is there for these findings?

This was a narrative review of 168 studies, not a primary clinical trial. While some links between gut metabolites and lung cancer are being studied, many parts of the system, such as the endocrine and neural dimensions, are not yet fully understood or proven to be causal.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedSep 2026
View Original Abstract ↓
The gut-lung axis, the long-range communication between the intestinal microbiota and the lungs, has been shown to influence immunotherapy responses in non-small-cell lung cancer (NSCLC). Existing reviews, however, focus almost exclusively on the chemical signaling dimension of microbial metabolites. The relay function of enteroendocrine hormones and the integrative role of the nervous system have yet to be incorporated into a unified framework. We searched seven databases (PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, Wanfang, and VIP) from inception to June 2026 for original studies and reviews addressing gut microbiota and lung-gut-brain axis mechanisms in the context of NSCLC or small-cell lung cancer. Two authors independently performed study selection, data extraction, and thematic classification. A narrative synthesis was conducted, with evidence organized along three signaling axes: soluble metabolites, the metabolic-endocrine axis, and neuroimmune integration. As a narrative review with a systematic search, this study was registered on PROSPERO (CRD420261425826), while formal risk-of-bias assessment and GRADE evaluation were not performed. A total of 168 studies was included (only a subset of these included studies cited in the main text). The volume of evidence across the three axes formed a pronounced gradient. Soluble metabolites (short-chain fatty acids, tryptophan metabolites, and bile acids) have been cross-validated in clinical cohorts, animal models, and in vitro experiments; fecal microbiota transplantation and prebiotic strategies have entered clinical trials. The metabolic-endocrine axis rests on a solid foundation in normal physiology, but the key bridging nodes in the NSCLC disease context remain untested. Evidence for the neuroimmune integration axis is the sparsest: the only support for a direct transport function of the vagus nerve comes from a non-peer-reviewed preprint in a non-cancer model, and the full neuroendocrine signal transduction chain remains hypothetical. To address this gap, we outline a pathway model annotated with evidence levels at each node. Research on the lung-gut-brain axis is heavily concentrated in the chemical dimension. The mechanistic gaps in the endocrine and neural dimensions represent the principal barrier for the field’s transition from correlational description to causal mechanism studies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.